KNSA Q3 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$99M+719.6% YoY

Gross Profit

$87M87.4% margin

Operating Income

$46M46.8% margin

Net Income

$224M226.0% margin

EPS (Diluted)

$3.18

QoQ Revenue Growth

+267.5%

Cash Flow

Operating Cash Flow

$62M

Free Cash Flow

$62M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$460M

Total Liabilities

$76M

Stockholders' Equity

$384M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$99M	$12M	+719.6%
Gross Profit	$87M	$8M	+949.6%
Operating Income	$46M	-$31M	+251.3%
Net Income	$224M	-$31M	+833.7%

Revenue Segments

Product

$33M100%